nmdp logo

After the Results: Quality of Life Pre- and Post-Transplant

The Role of Transplant for Treating MDS in Older Patients

March 17, 2022 

Target Audience

This educational activity is intended for physicians, nurses and other members of the health care team who care for patients who may benefit from hematopoietic stem cell transplantation.

Program Overview

The results of recent research on hematopoietic cell transplantation (HCT) for older adults with high-risk MDS has implications for community hematologists/oncologists. During this 60-minute on-demand webinar, the panel explores the implications from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1102 study a multicenter, biologic assignment trial in older patients with high-risk MDS to define the benefit of HCT over non-HCT therapy.

Those results include a finding that demonstrates quality of life and functional performance status are better than age when determining eligibility for HCT for older patients with high-risk MDS. With HCT remaining the only curative therapy for MDS, those factors must be taken into consideration when assessing treatment options for older patients with high-risk MDS.

Interested in claiming CME or CE credit?

Be sure to complete the pre-test here, then complete the post-test after watching the webinar. The post-test link can be found in the on-demand webinar platform in the related resources tab. For more information, see the Instructions for participation and requesting credit section below.

Access on-demand webinar

Learning Objectives

Upon completion of this course, the learners should be able to:

  • Review the BMT CTN 1102 study results
  • Explain how quality of life and functional performance status are better than age in determining eligibility for HCT
  • Describe how advances in HCT facilitate improved survival and preserve quality of life
  • Discuss the implications of the study findings for community hematologists/oncologists who see patients with MDS
  • Describe the best practices for referring patients to a transplant center early for HCT consultation

Faculty

Abhinav B. Chandra, MD, MSc, FACP, MBA
Medical Director
Yuma Regional Medical Center Cancer Center

Corey S. Cutler, MD, MPH, FRCP(C)
Medical Director (Stem Cell Transplantation Program)
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School

Rachel Cusatis, PhD 
Assistant Professor of Medicine
Medical College of Wisconsin
Scientific Director of Patient Centered Research & Survivorship
CIBMTR® (Center for International Blood and Marrow Transplant Research®)

Stephen Spellman, MBS 
Vice President of Research and Senior Scientific Director
CIBMTR
NMDP 

Tamila Kindwall-Keller, DO 
Professor of Medicine
Medical Director (Cellular Immunotherapy and Stem Cell Transplant Program)
MetroHealth Medical Center

Planning Committee

Abhinav B. Chandra, MD, MSc, FACP, MBA
Medical Director
Yuma Regional Medical Center Cancer Center

Anna Cincotta, FNP
Senior Clinical Operations Partner
NMDP

Corey S. Cutler, MD, MPH, FRCP(C)
Medical Director (Stem Cell Transplantation Program)
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School

Heather Stefanski, MD, PhD
Vice President of Medical Services
NMDP

Rachel Cusatis, PhD 
Assistant Professor of Medicine
Medical College of Wisconsin
Scientific Director of Patient Centered Research & Survivorship
CIBMTR® (Center for International Blood and Marrow Transplant Research®)

Stephen Spellman, MBS 
Vice President of Research and Senior Scientific Director
CIBMTR
NMDP

Tamila Kindwall-Keller, DO 
Professor of Medicine
Medical Director (Cellular Immunotherapy and Stem Cell Transplant Program)
MetroHealth Medical Center

Instructions for participation and requesting credit

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the post-test is required to successfully complete this activity. The participant may take the test until successfully passed.

If you are requesting AMA credits, ANCC credits or a certificate of participation, your certificate will be available for download.

Accredited provider

This activity is jointly provided by The France Foundation and NMDP.

Accreditation statement
In support of improving patient care, this activity has been planned and implemented by The France Foundation and NMDP. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit designation

  • Physicians: The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • Nurses: The France Foundation designates this activity for 1.0 contact hour.
  • Other healthcare professionals: All other health care professionals completing this course will be issued a statement of participation.

Disclosure policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and NMDP require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and NMDP resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and NMDP to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and NMDP are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

Name of Individual Individuals Role in Activity Name of Commercial Entity Nature of Relationship(s) Mechanism(s) implemented to resolve conflict of interest
Abhinav B. Chandra, MD, MSc, FACP, MBA Planning Committee Member, Faculty Tempus Lab Consultant All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member

Content was reviewed by a non-conflicted member of the Planning Committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Anna Cincotta, FNP Planning Committee, Content Reviewer No relevant financial disclosures NA NA
Corey S. Cutler, MD, MPH, FRCP(C) Planning Committee Member, Faculty No relevant financial disclosures NA NA
Heather Stefanksi, MD, PhD Planning Committee, Content Reviewer Novartis Non-CE Consulting The financial relationship with Novartis ended in April 2021.
Heather Tarbox, MPH TFF Staff No relevant financial disclosures NA NA
Jas Chahal, PhD TFF Staff No relevant financial disclosures NA NA
Karla Dawson, MPH NMDP Staff No relevant financial disclosures NA NA
Kelly Wilson, MSN, RN NMDP Staff No relevant financial disclosures NA NA
Rachel Cusatis, PhD Planning Committee, Faculty No relevant financial disclosures NA NA
Samantha Watters, MPH NMDP Staff No relevant financial disclosures NA NA
Stephen Spellman, MBS Planning Committee Member, Moderator No relevant financial disclosures NA NA
Tamila Kindwall-Keller, DO Planning Committee, Faculty 1. OrcaBIO
2. BMT CTN
1. Data & Safety Monitoring Board
2. Medical Monitor/ Non-CE Consulting
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member.

Content was reviewed by a non-conflicted member of the Planning Committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.

Disclosure of unlabeled use

TFF and NMDP require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and NMDP do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

TFF and NMDP present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, NMDP, and the commercial supporter(s) assume no liability for the information herein.

Copyright information

Copyright ©2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission

Privacy policy

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundations Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

Contact information

If you have questions about this CME activity, please contact The France Foundation at (860) 434-1650 or info@francefoundation.com.

Resources

Full study published in the Journal of Clinical Oncology 

BMT CTN 1102 quality of life research summary